JAZZ PHARMACEUTICALS: ESTIMATED Q3 2026 IPR&D CHARGE TO UNFAVORABLY IMPACT GAAP EPS & NON-GAAP ADJ EPS BY $11 - SEC FILING

Reuters · 1d ago

Please log in to view news